乙型肝炎病毒感染者经治疗后病毒已清除，接受免疫抑制治疗时乙型肝炎再激活是否会被忽视？
Could Hepatitis B Reactivation be Overlooked in Patients with Resolved Hepatitis B Virus Infection and Receiving Immunosuppressive Treatment?
机构信息
Department of Gastroenterology, Amasya University Sabuncuoğlu Şerefeddin Training and Research Hospital, Amasya, Turkey.
Department of Gastroenterology, Sakarya University Faculty of Medicine, Sakarya, Turkey.
出版信息
Turk J Gastroenterol. 2024 Apr;35(4):350-351. doi: 10.5152/tjg.2024.23534.
Abstract
Cite this article as: Acar Ş, Eminler AT. Could hepatitis B reactivation be overlooked in patients with resolved hepatitis B virus infection and receiving immunosuppressive treatment? Turk J Gastroenterol. 2024;35(4):350-351.
摘要
引用本文
Acar Ş, Eminler AT. 已治愈乙型肝炎病毒感染并接受免疫抑制治疗的患者中乙型肝炎再激活是否会被忽视？土耳其胃肠病学杂志。2024;35(4):350-351.
相似文献
1
Could Hepatitis B Reactivation be Overlooked in Patients with Resolved Hepatitis B Virus Infection and Receiving Immunosuppressive Treatment?乙型肝炎病毒感染者经治疗后病毒已清除，接受免疫抑制治疗时乙型肝炎再激活是否会被忽视？
Turk J Gastroenterol. 2024 Apr;35(4):350-351. doi: 10.5152/tjg.2024.23534.
2
RE: Could Hepatitis B Reactivation Be Overlooked in Patients with Resolved HBV Infection and Receiving Immunosuppressive Treatment?主题：乙肝病毒感染已康复且正在接受免疫抑制治疗的患者是否会被忽视乙肝病毒再激活？
Turk J Gastroenterol. 2024 Mar 31;35(4):352-353. doi: 10.5152/tjg.2024.235342.
3
Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis.化疗或免疫抑制药物治疗期间的抗病毒预防，以防止HBV感染已治愈患者的HBV再激活：一项系统评价和荟萃分析。
Eur J Clin Pharmacol. 2018 Sep;74(9):1111-1119. doi: 10.1007/s00228-018-2487-4. Epub 2018 May 29.
4
Updates on management strategies of hepatitis B virus reactivation in patients with resolved hepatitis virus B infection undergoing immunosuppressive therapy in rheumatology and the current situation in Niigata Rheumatic Center.乙型肝炎病毒再激活管理策略的最新进展，针对风湿免疫科接受免疫抑制治疗的乙型肝炎病毒感染已缓解患者，以及新潟风湿中心的现状。
Mod Rheumatol. 2021 Jul;31(4):775-782. doi: 10.1080/14397595.2020.1832731. Epub 2020 Oct 29.
5
Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy.需要免疫抑制治疗的乙肝病毒（HBV）感染患者中HBV再激活的特征、预防及管理
J Infect Dis. 2017 Nov 16;216(suppl_8):S778-S784. doi: 10.1093/infdis/jix178.
6
A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection.从真实临床实践看免疫抑制导致 HBV 再激活的病毒学表现和结局：死亡风险增加和由潜伏感染向慢性感染演变的证据。
J Viral Hepat. 2019 Jul;26(7):846-855. doi: 10.1111/jvh.13101. Epub 2019 May 14.
7
American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.美国胃肠病学会关于免疫抑制药物治疗期间预防和治疗乙型肝炎病毒再激活的指南。
Gastroenterology. 2015 Jan;148(1):215-9; quiz e16-7. doi: 10.1053/j.gastro.2014.10.039. Epub 2014 Oct 31.
8
Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.接受化疗或免疫抑制治疗的乙肝病毒感染已康复患者中的乙肝病毒再激活
Eur J Gastroenterol Hepatol. 2018 Aug;30(8):925-929. doi: 10.1097/MEG.0000000000001130.
9
Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.HBsAg 阳性的风湿性疾病患者在接受抗肿瘤坏死因子治疗或 DMARDs 治疗时乙型肝炎病毒再激活。
Int J Rheum Dis. 2013 Oct;16(5):527-31. doi: 10.1111/1756-185X.12154.
10
Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.直接作用抗病毒药物治疗丙型肝炎期间乙型肝炎病毒再激活：系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):172-180. doi: 10.1016/S2468-1253(18)30002-5. Epub 2018 Jan 19.
引用本文的文献
1
Infection Risk and Vaccination in the Management of Psoriasis: Considerations for Biologic Therapy.银屑病管理中的感染风险与疫苗接种：生物治疗的考量
Psoriasis (Auckl). 2025 Apr 11;15:127-144. doi: 10.2147/PTT.S510141. eCollection 2025.
2
RE: Could Hepatitis B Reactivation Be Overlooked in Patients with Resolved HBV Infection and Receiving Immunosuppressive Treatment?主题：乙肝病毒感染已康复且正在接受免疫抑制治疗的患者是否会被忽视乙肝病毒再激活？
Turk J Gastroenterol. 2024 Mar 31;35(4):352-353. doi: 10.5152/tjg.2024.235342.
本文引用的文献
1
Risk of Hepatitis B Virus Reactivation in Patients with Resolved Infection on Therapy with Corticosteroids and Conventional Synthesis Immunosuppressants for Kidney Disease: A Single-Center Analysis of 258 Patients.接受皮质类固醇和常规合成免疫抑制剂治疗的肾病患者中已解决感染患者乙型肝炎病毒再激活的风险：单中心 258 例患者分析。
Turk J Gastroenterol. 2023 Oct;34(10):1035-1040. doi: 10.5152/tjg.2023.22511.
2
Biologic Therapy Carries a Very Low Risk of Reactivation in Hepatitis B Surface Antigen-Negative Phase of Hepatitis B.生物疗法在乙型肝炎表面抗原阴性期乙型肝炎中复发的风险非常低。
Turk J Gastroenterol. 2023 Feb;34(2):156-160. doi: 10.5152/tjg.2022.22196.
3
HBV flare associated with immunosuppressive treatments: it is still dangerous in the third-generation antivirals era.与免疫抑制治疗相关的乙肝病毒再激活：在第三代抗病毒药物时代仍然危险。
Antivir Ther. 2020;25(3):121-129. doi: 10.3851/IMP3356.
4
Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study.监测乙型肝炎病毒 (HBV) DNA 与 B 细胞淋巴瘤中 HBV 再激活的风险：一项前瞻性观察性研究。
Clin Infect Dis. 2015 Sep 1;61(5):719-29. doi: 10.1093/cid/civ344. Epub 2015 May 1.
5
American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.美国胃肠病学会关于免疫抑制药物治疗期间预防和治疗乙型肝炎病毒再激活的指南。
Gastroenterology. 2015 Jan;148(1):215-9; quiz e16-7. doi: 10.1053/j.gastro.2014.10.039. Epub 2014 Oct 31.
Zotero 插件